MetaCap

TuHURA Biosciences (HURA) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TuHURA Biosciences (HURA) has outperformed Upstream Bio (UPB) over the past year, losing 28.2% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $82.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HURA-28.16%UPB-93.78%
+90%-6%-103%
Nov 21, 20251 yearNov 20, 2026
HURA-79.94%UPB-92.77%
+48%-26%-99%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HURA versus UPB key metrics
MetricHURAUPB
Share price$1.25$1.59
Market cap$82.20M$87.15M
1-day change-8.09%-20.50%
YTD return+65.13%-94.14%
1-year return-28.16%-93.78%
5-year return-99.91%—
EPS (TTM)$-0.50$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-30.05M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$3.43$33.68
52-week low$0.41$1.56
Distance from 52-week high-63.56%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+543.20%+1245.91%
Average volume329.76K1.01M
Shares outstanding65.76M54.81M
Employees2275
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HURA has outperformed UPB by 65.6 percentage points over the past year.

About TuHURA Biosciences

HURA stock →

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

HURA vs UPB FAQ

Which is bigger, TuHURA Biosciences or Upstream Bio?

Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $82.20M for TuHURA Biosciences (HURA).

Which stock has performed better over the past year, HURA or UPB?

HURA returned -28.16% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are TuHURA Biosciences and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons